阿帕替尼联合三线化疗治疗晚期非小细胞肺癌的临床疗效观察

Observation on clinical efficacy of apatinib combined with third-line chemotherapy in the treatment of advanced non-small cell lung cancer

目的评价阿帕替尼联合三线化疗治疗晚期非小细胞肺癌(NSCLC)的可行性和临床整体疗效。方法 96例晚期NSCLC患者,以随机法分为对照组及研究组,各48例。对照组采取三线化疗治疗,研究组在对照组基础上联合阿帕替尼治疗。比较两组的近期疗效、副反应发生情况、血清肿瘤标志物[癌抗原125(CA125)、癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)]水平、体力以及生活质量。结果研究组近期治疗总有效率62.50%高于对照组的41.67%,差异具有统计学意义(P<0.05);两组副反应发生率比较差异无统计学意义(P>0.05)。研究组卡氏功能状态量表(KPS)评分(77.80±3.50)分、生活质量(QOL)评分(48.50±1.80)分高于对照组的(73.50±2.30)、(43.30±1.50)分, CA125(8.95±1.18)U/ml、CEA(4.36±0.66)ng/ml、CYFR21-1(3.50±0.55)ng/ml低于对照组的(15.43±2.05)U/ml、(6.75±0.75)ng/ml、(5.35±0.80)ng/ml,差异具有统计学意义(P<0.05)。结论阿帕替尼联合三线化疗治疗晚期NSCLC,在提升患者近期疗效、体力、生活质量以及降低血清肿瘤标志物的基础上未增加副作用,整体效果理想。

Objective To evaluate the feasibility and overall clinical efficacy of apatinib combined with third-line chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 96 patients with advanced NSCLC were randomly divided into control group and research group,with 48 cases in each group.The control group was treated with third-line chemotherapy,and the research group was treated with apatinib based on the control group.The short-term efficacy,occurrence of side effect,serum tumor markers[cancer antigen 125(CA125),carcinoembryonic antigen(CEA),cytokeratin 19 fragment(CYFRA21-1)]levels,physical strength and quality of life were compared between the two groups.Results The short-term efficacy 62.50%of the research group was higher than 41.67%of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of side effects between the two groups(P>0.05).The Karnofsky performance scale(KPS)score(77.80±3.50)points and quality of life(QOL)score(48.50±1.80)points of the research group were higher than(73.50±2.30)and(43.30±1.50)points of the control group,and CA125(8.95±1.18)U/ml,CEA(4.36±0.66)ng/ml,CYFR21-1(3.50±0.55)ng/ml were lower than(15.43±2.05)U/ml,(6.75±0.75)ng/ml,(5.35±0.80)ng/ml of the control group.All the difference was statistically significant(P<0.05).Conclusion In the treatment of advanced non-small cell lung cancer,apatinib combined with third-line chemotherapy can improve the short-term efficacy,physical strength,quality of life and reduces serum tumor markers without increase of side effects,and the overall effect is satisfactory.